Darwinian evolution created rare catalytic antibodies that eliminate disease-causing proteins 1000x more powerfully than regular antibodies. Synthetic biology harnesses them to create next generation therapies, vaccines, and diagnostics.
In this video you will learn about:
- The discovery of naturally occurring antibodies with powerful, disease-fighting enzymatic activity
- The synthetic biology platform that makes possible the selection and induction of such catabodies that target any disease-causing protein
- Case study: creating the world’s first HIV vaccine that destroys strains from around the world.
- Case study: breakthrough Alzheimer’s therapy that improves brain function
- Massively improving immunoassay sensitivity with irreversible antibodies for any target
- What the future holds…. unleashing the enormous therapeutic potential of catabodies for neurology, cardiovascular, allergy, autoimmune, cancer, infectious disease, and more
Speaker: Sudhir Paul, Ph.D., CSO & Co-Founder of Covalent Bioscience
Paul’s work as a Professor at the Universities of Nebraska and Texas has brought catabodies/E-vaccines from chemical curiosities to the threshold of medical use. His research has been funded continuously by the NIH, non-profit foundations and biotech companies since 1983. He discovered harmful catabodies in autoimmune disease, progressing to devising Covalent’s synthetic biology platform for generating catabodies and E-vaccines for disease treatment and prevention. He has authored more than 200 original research articles and edited several books. Paul co-founded Covalent Bioscience. In 2018, he moved fulltime to Covalent to translate his know-how and inventions for medical benefit.
Covalent Bioscience is a Texas-based company with a disruptive new approach for developing superior drugs, vaccines and diagnostsics based on catabodies, irreversible antibodies, and E-vaccines (electrophilic vaccine). Covalent’s patented technology can deliver novel catabodies, irreversible antibodies, and E-vaccines against any pre-defined target in under 6 months.
Host: William Kazman, Founding Partner of GeneWorx Capital
MIT-trained engineer/entrepreneur and enthusiast of the biological revolution and its accelerating global impact. Applying 30+ years of engineering and company-building skills to identify early stage biological innovations with disruptive potential, and help their inventors/scientists/entrepreneurs transform them into high value enterprises.
GeneWorx Capital is a venture development firm in Cambridge, MA comprised of MIT technologists, former Wall Street VC investors and Silicon Valley entrepreneurs on a mission to accelerate the growth of emerging life science companies.